HI
RPRX icon

Harbour Investments’s Royalty Pharma RPRX Stock Holding History

Harbour Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7K Buy
370
+49
+15% +$2.55K ﹤0.01% 2927
2026
Q1 		$15.4K Buy
321
+17
+6% +$745 ﹤0.01% 3030
2025
Q4 		$11.7K Buy
304
+19
+7% +$725 ﹤0.01% 2671
2025
Q3 		$10K Buy
285
+1
+0.4% +$36 ﹤0.01% 2690
2025
Q2 		$10.2K Buy
284
+24
+9% +$795 ﹤0.01% 2558
2025
Q1 		$8.11K Sell
260
-83
-24% -$2.63K ﹤0.01% 2616
2024
Q4 		$8.75K Buy
343
+16
+5% +$424 ﹤0.01% 2507
2024
Q3 		$9.25K Sell
327
-2,897
-90% -$80.2K ﹤0.01% 2387
2024
Q2 		$85K Buy
3,224
+2,712
+530% +$75.2K ﹤0.01% 1307
2024
Q1 		$15.6K Buy
512
+56
+12% +$1.65K ﹤0.01% 2059
2023
Q4 		$12.8K Buy
456
+214
+88% +$5.88K ﹤0.01% 2060
2023
Q3 		$6.56K Buy
242
+222
+1,110% +$6.59K ﹤0.01% 2187
2023
Q2 		$615 Hold
20
– – ﹤0.01% 2780
2023
Q1 		$721 Buy
+20
New +$742 ﹤0.01% 2747

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbour Investments's RPRX Position: Q2 2026 in Review

Harbour Investments increased its Royalty Pharma (RPRX) stake by 15% in Q2 2026, buying an estimated $2.55K and bringing the position to 370 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2927.

Harbour Investments first reported a position in RPRX in Q1 2023 and has held it in 14 quarters since. The position peaked at $85K in Q2 2024. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Harbour Investments held 370 shares of Royalty Pharma worth $20.7K as of Q2 2026.
  • Harbour Investments bought 49 Royalty Pharma shares in Q2 2026, an estimated $2.55K.
  • Royalty Pharma made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #2927 holding.
  • Harbour Investments first reported a position in Royalty Pharma in Q1 2023 and has held it in 14 quarters since.
  • Harbour Investments's Royalty Pharma position peaked at $85K in Q2 2024.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.